MAGEA3 and pituitary cancer: In addition, although MAGE-A3 has been demonstrated to possess tumor-promoting capabilities, functional studies have only been performed with thyroid and pituitary cancer cells [94, 95] and, to our knowledge, functional studies on MAGE-A3 have not been performed using NSCLC or melanoma cells.